Loading patent…
AssigneesIcahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme Corp.
InventorsPeter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Svetlana Sadekova, Rachel Allison Altura, Uyen Phan, Brian B. Haines, Jedd D. Wolchok
Estimating the term…
Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.
A first composition for use in a method for treating cancer in a human subject, wherein the first composition comprises a chimeric Newcastle disease virus (NDV), wherein the chimeric NDV comprises a packaged genome comprising a transgene encoding human interleukin-12 (“IL-12”), wherein the transgene encodes a human IL-12 p40 subunit and a human IL-12 p35 subunit, and wherein the method further comprises administering a second composition, wherein said second composition comprises an antibody that binds to human PD-1, and blocks the interaction between human PD-1 and its ligands, PD-L1 and PD-L2.
A chimeric NDV comprising a packaged genome, said packaged genome comprising a transgene encoding a human IL-12, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:39 or 22.
A chimeric NDV comprising a packaged genome, said packaged genome comprising a transgene encoding a human IL-12, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:43 or 42.
Dependencies are inferred from the claim text.